Methods and sources

Review the scientific sources, structure records, and computational methods used in this campaign. Follow the source links to the underlying measurements and models.

Research inputs and molecular work

01Disease and cells
Literature, disease associations, and cell-expression records.
02Surface proteins
Protein identities, extracellular regions, and known interventions.
03Structures and sites
Sequences, molecular partners, and deposited binding interfaces.
04 · PARALLEL WORKScreen or design
Molecules → docking poses Protein designs → sequences and models

How the campaign was run

Investigate disease and cell biology

Literature, disease associations, and cell-expression records informed the target census. Protein annotations identified surface location and extracellular regions.

PubMed · preprints · Open Targets · Cancer Surfaceome Atlas · Human Protein Atlas · cBioPortal · UniProt

Review source coverage →

Resolve structures and molecular partners

Sequence and structure records connected targets to extracellular domains, deposited binding partners, and defined molecular sites. Compound databases supplied identities and measured activity records.

RCSB PDB · AlphaFold DB · PubChem · ChEMBL · BindingDB

Inspect molecular structures →

Screen molecules and design binders

Smina/Vinardo screened defined FAP and CD73 pockets. Codex Binder Lane organized protein-design campaigns around target constructs, binding sites, reference controls, and candidate evaluation.

RFdiffusion3 · ProteinMPNN · BoltzGen · Proteina Complexa · PXDesign · Boltz-2 · Executed through FAL, including Boltz-2 complex prediction

Read the executed campaigns →

Research plans and detailed campaign methods

Research plans and computational results

ITGB6 · protein-binder design

O-ITGB6-8TCG-REFERENCE-RECOVERY

The deposited target–minibinder complex provides a reference binding interface for checking target preparation and generated candidate geometry.

Format: miniprotein
Site: reference-interface
Desired effect: Recover the deposited B6_BP_dslf footprint as a target-conditioned positive control for the structure-to-design lane.
Recorded method status: deposited-complex-evaluation
Result ingestion: partial-stop-gate-fired

Recorded risks

A recovered reference footprint validates geometric conditioning and transport; it does not establish binding affinity, selectivity, or therapeutic activity.
The beta-6 conditioning subset represents an interface that also contacts alpha-v chain A.

completed computational geometry-recovery screen with no promoted generated candidate

Site evidence and residue mapping

Site mode: reference-interface
Evidence class: experimental-reference-binder-interface
Evidence: Ten beta-6 residues were selected deterministically from the heavy-atom contact network observed between target chains A/B and deposited minibinder chain C in RCSB 8TCG. The complete 33-residue target footprint and all 60 residue contact pairs remain in the interface artifact.
Numbering: RCSB author numbering mapped to sequential campaign numbering per target chain
Excluded regions: deposited minibinder chain C, nonpolymer glycans and metal ions in the RFdiffusion3 compatibility input
Uncertain regions: alpha-v chain A contributes 11 observed interface residues but is retained as receptor context rather than a conditioning-hotspot chain

{
  "campaign_site_lock_id": "SITE-8TCG-BETA6-REFERENCE",
  "source_actionable_site_id": "SITE-RCSB-8TCG-b6-bp-dslf-miniprotein",
  "mode": "reference-interface",
  "numbering_scheme": "RCSB author numbering mapped to sequential campaign numbering per target chain",
  "residues": [
    {
      "campaign_chain_id": "B",
      "campaign_residue_number": 71,
      "author_residue_number": "183",
      "insertion_code": null
    },
    {
      "campaign_chain_id": "B",
      "campaign_residue_number": 14,
      "author_residue_number": "126",
      "insertion_code": null
    },
    {
      "campaign_chain_id": "B",
      "campaign_residue_number": 107,
      "author_residue_number": "219",
      "insertion_code": null
    },
    {
      "campaign_chain_id": "B",
      "campaign_residue_number": 17,
      "author_residue_number": "129",
      "insertion_code": null
    },
    {
      "campaign_chain_id": "B",
      "campaign_residue_number": 109,
      "author_residue_number": "221",
      "insertion_code": null
    },
    {
      "campaign_chain_id": "B",
      "campaign_residue_number": 106,
      "author_residue_number": "218",
      "insertion_code": null
    },
    {
      "campaign_chain_id": "B",
      "campaign_residue_number": 15,
      "author_residue_number": "127",
      "insertion_code": null
    },
    {
      "campaign_chain_id": "B",
      "campaign_residue_number": 204,
      "author_residue_number": "316",
      "insertion_code": null
    },
    {
      "campaign_chain_id": "B",
      "campaign_residue_number": 108,
      "author_residue_number": "220",
      "insertion_code": null
    },
    {
      "campaign_chain_id": "B",
      "campaign_residue_number": 105,
      "author_residue_number": "217",
      "insertion_code": null
    }
  ],
  "evidence": "Ten beta-6 residues were selected deterministically from the heavy-atom contact network observed between target chains A/B and deposited minibinder chain C in RCSB 8TCG. The complete 33-residue target footprint and all 60 residue contact pairs remain in the interface artifact.",
  "evidence_class": "experimental-reference-binder-interface",
  "excluded_regions": [
    "deposited minibinder chain C",
    "nonpolymer glycans and metal ions in the RFdiffusion3 compatibility input"
  ],
  "uncertain_regions": [
    "alpha-v chain A contributes 11 observed interface residues but is retained as receptor context rather than a conditioning-hotspot chain"
  ],
  "reference_interface_id": "IF-RCSB-8TCG-AB-C",
  "full_observed_target_interface_residue_count": 33
}

FAP · small-molecule screening

O-FAP-6Y0F-DEFINED-POCKET-SCREEN-HANDOFF

The deposited linagliptin pocket supplied a locked extracellular FAP chain-A control and passed the unchanged redocking gate after charge-aware receptor preparation.

Format: Not recorded
Site: SITE-RCSB-6Y0F-linagliptin
Desired effect: Record the completed FAP/6Y0F charge-aware docking screen as a hypothesis-generation handoff; do not infer affinity or inhibition.
Recorded method status: completed-defined-pocket-computational-screening

Recorded risks

Docking scores and pose geometry are computational hypotheses only.
The five confirmation passers retain reactivity, aggregation, solubility, and assay-interference review flags where recorded.
No measured binding, target engagement, or disease efficacy is established.

Not classified

Screening results

Run: fap-6y0f-defined-pocket-screen-v1
Recorded outcome: completed-control-qualified
Screening hypotheses: 24
Candidates passing geometry and repeat-run checks: NP011, NP004, NP015, NP021, NP001
Protein-binder promotions: 0
Run manifest SHA-256: 02cf4d95cb5cb350bc2753299af01b874f00ec56a350d09d356dd500322a0029
Confirmation plan SHA-256: ea69040c2b09aafa310673c94bc8adbeec3b3709b6f563864d65e5aadb6a20c0

NT5E (CD73) · small-molecule screening

O-NT5E-9R0G-DEFINED-POCKET-SCREEN-HANDOFF

The deposited A1JCG control passed the initial and confirmation pose checks for geometry and metal contact.

Format: Not recorded
Site: SITE-RCSB-9R0G-cd73-compound-21
Desired effect: Record the completed CD73/9R0G screen as a computational pose-ranking hypothesis handoff with its metal-contact control evidence.
Recorded method status: completed-defined-pocket-computational-screening

Recorded risks

The legacy Smina preparation and score are not affinity or inhibition measurements.
A prior tracked canary-failure interpretation is retained as superseded evidence, not erased.
No measured binder or therapeutic claim follows from the five confirmation passers.

Not classified

Screening results

Run: nt5e-9r0g-defined-pocket-screen-v1
Recorded outcome: completed-control-qualified; prior canary-failure tracking claim superseded by output-grounded validation
Screening hypotheses: 24
Candidates passing geometry and repeat-run checks: NP011, NP005, NP015, NP013, NP012
Protein-binder promotions: 0
Run manifest SHA-256: 53b5485438a3478ff509c7ac62f9506251a70d83e1d00295a67f9d98178ae0bd
Confirmation plan SHA-256: 279365e276263d2f02dfc80d2eb898d6c6f46df7e7df3495dfc25f657fa18c6b

CEACAM5 · candidate and control comparison

O-CEACAM5-8BW0-THREE-ARM-CHECKPOINT-HANDOFF

The three-arm comparison completed six predictions and local remeasurement. The positive control failed the interface-score and contact-margin requirements.

Format: Not recorded
Site: SITE-RCSB-8BW0-tusamitamab-fab
Desired effect: Preserve the executed CEACAM5 A3-B3 checkpoint stop as an explicit non-promotion decision.
Recorded method status: executed-control-failed-checkpoint
Checkpoint protein-binder promotions: 0

Recorded risks

Two generated candidates passed the candidate geometry gate before the control stop; they are not promoted binders.
The checkpoint does not settle the independent four-arm campaign.
No binding, selectivity, or therapeutic activity was established.

Not classified

CEACAM5 · comparison of four design methods

O-CEACAM5-8BW0-FOUR-ARM-OUTCOME

Three methods generated nine 64-residue candidates; four passed the predefined local geometry criteria. FreeBindCraft returned no candidate, leaving the four-method comparison incomplete.

Format: Not recorded
Site: SITE-RCSB-8BW0-tusamitamab-fab
Desired effect: Preserve the original four-arm campaign as a completed partial result with an explicit incomplete-cohort stop.
Recorded method status: executed-stop-incomplete-four-arm-cohort
Campaign protein-binder promotions: 0

Recorded risks

The four local geometry passers have no common independent score in this campaign and are not promoted.
FreeBindCraft produced no scored candidate because the prediction service failed.
The separate three-arm checkpoint does not retroactively complete this four-arm comparison.

Not classified

CEACAM5 · paired antibody-domain prediction

O-CEACAM5-8BW0-PAIRED-FV-DIAGNOSTIC

The CEACAM5 Fab interface includes two antibody variable domains. The study evaluated one prediction with both domains to test the control setup.

Format: Not recorded
Site: SITE-RCSB-8BW0-tusamitamab-fab
Desired effect: Test whether a paired tusamitamab VH/VL control context resolves the single-domain control ambiguity before any further CEACAM5 binder qualification.
Recorded method status: executed-bounded-diagnostic-stopped-on-scorer-incompatibility
Diagnostic protein-binder promotions: 0

Recorded risks

The scorer lacked the residue map required for a three-chain ipSAE calculation.
The observed union of chains B and C is a context diagnostic and not a promotable binder candidate.
No binding, selectivity, pharmacology, or therapeutic activity was established.

Not classified

CEACAM5 · comparison of replacement design methods

O-CEACAM5-8BW0-REPLACEMENT-GENERATOR-OUTCOME

The replacement campaign used Genie3 and ESMFold2 to test recovery of the tusamitamab binding interface after the FreeBindCraft prediction failed.

Format: Not recorded
Site: SITE-RCSB-8BW0-tusamitamab-fab
Desired effect: Evaluate bounded Genie3 site-conditioned and ESMFold2 unconditioned replacement-generator routes under the frozen CEACAM5 target-recovery and site-contact gates.
Recorded method status: executed-bounded-replacement-generator-comparison-no-promotion
Campaign protein-binder promotions: 0

Recorded risks

The Genie3 trace recovered the requested site footprint but failed the frozen target-coordinate lock, so sequence filling and scale generation were not allowed.
ESMFold2 was unconditioned and generated exploratory folds rather than target-site-conditioned binders; all three failed the frozen site-contact gate.
None of the four structures was promoted or shown to bind CEACAM5.

Not classified

Scientific source summary

Scientific results and sources

Read campaign outcomes and follow the source links for the reported measurements.

Sources used in the campaign

Collection counts and target reconciliation

Normalized entities: 601
Surface targets: 185
Excluded from surface universe: 334
Unresolved records: 82

Evidence corpus

Unique literature records: 2,570
Duplicate query memberships: 46
Missing or merged PMIDs: 24
Reviewed UniProt matches: 592
Global surface-protein records: 3,567
COAD-specific surface candidates: 22
Single-cell gene rows: 899
Registry studies: 495
Registry intervention entries: 1,335
Target assignments: 140
Distinct experimental PDB entries: 15

Evidence sources and their recorded retrieval status.
Source	Status	Records	Source details
PubMed literature	partial	2,570	Records and retrieval notes unique PubMed records Limitation: Three PubMed query families yielded 2,570 unique records from 2,616 query memberships; 24 requested PMIDs were missing or merged. The source snapshot is bounded to the registered query families. Source query Q-LIT-001 Evidence class literature-and-preprints Retrieved 2026-09-04
Preprint searches	complete	13	Records and retrieval notes unique preprint DOI records Limitation: All 40 registered concepts completed at a hard 100-record-per-concept cutoff; 0 reached the cutoff. 6 unique 10.1101 records were hydrated; 7 other DOI records remain discovery metadata rather than bioRxiv/medRxiv hydrations. Source query Q-PREPRINT-001 Evidence class literature-and-preprints Retrieved 2026-09-04
Disease-target search	complete	601	Records and retrieval notes The search combined 558 Open Targets associated-target records with 43 query additions, producing 601 normalized entities. normalized disease-linked entities Source query Q-CANCER-001 Evidence class cancer-genomics-and-expression Retrieved 2026-09-04
cBioPortal RNA expression	partial	184	Records and retrieval notes retained targets mapped to the declared cBioPortal cohort Limitation: Mapped 184 of 185 retained targets and retained 107,566 transcript-expression measurements. Unresolved: T-ENSG00000130202 (PVRL2). This is a public-cohort MSS proxy, not patient-specific protein or surface abundance. Source query Q-CBIO-001 Evidence class cancer-genomics-and-expression Retrieved 2026-09-04
Cancer Surfaceome Atlas	complete	3,567	Records and retrieval notes global Cancer Surfaceome Atlas GESP records Source query Q-PROTEOME-001 Evidence class surface-and-proteome-studies Retrieved 2026-09-04
Single-cell RNA expression	partial	899	Records and retrieval notes Cancer Surfaceome Atlas single-cell gene rows Limitation: The snapshot includes the published COAD single-cell expression matrix; it does not include a patient-specific single-cell or spatial dataset. Source query Q-CELL-001 Evidence class single-cell-and-spatial-context Retrieved 2026-09-04
Human Protein Atlas	partial	184	Records and retrieval notes retained targets represented in the HPA normal-tissue overlay Limitation: Human Protein Atlas normal-tissue summaries represent 184 of 185 retained targets. Unresolved: T-NECTIN4 (NECTIN4). The overlay is expression context, not accessible surface density or a therapeutic-index model. Source query Q-NORMAL-001 Evidence class normal-tissue-and-cell-context Retrieved 2026-09-04
Canonical sequences and topology	partial	185	Records and retrieval notes retained targets with canonical protein sequence and reviewed topology Limitation: Canonical sequence and reviewed topology are present for 185 of 185 retained targets, with 0 unresolved canonical records. Target-specific isoform and proteoform reconciliation remains outside this collection. Source query Q-SEQ-001 Evidence class sequence-topology-and-proteoforms Retrieved 2026-09-05
ClinicalTrials.gov studies	partial	495	Records and retrieval notes unique ClinicalTrials.gov studies Limitation: ClinicalTrials.gov yielded 766 normalized intervention candidates and 140 target assignments. Bounded measured activity evidence for Structure-A targets is recorded separately under Q-ACTIVITY-001; neither lane is an exhaustive intervention review. Source query Q-THERAPY-001 Evidence class interventions-and-trials Retrieved 2026-09-04
ChEMBL and BindingDB	partial	57	Records and retrieval notes Read details measured ChEMBL or BindingDB protein-target activity records Limitation: The bounded Structure-A pass ran 73 registered queries for 10 targets and retained 57 measured records: 31 from ChEMBL and 26 from BindingDB. 8 PDB-indexed BindingDB queries failed. All records remain target-level or PDB-indexed target matches without extracellular-site localization; none establishes action, selectivity, safety, or efficacy. Source query Q-ACTIVITY-001 Evidence class interventions-and-trials Retrieved 2026-09-05
Experimental PDB structures	partial	15	Records and retrieval notes distinct verified experimental RCSB PDB entries Limitation: The library contains 15 distinct experimental PDB entries and 16 total records, including 1 target-only compatibility record. Accession-level deposited complex searches are not complete for every retained target. Source query Q-STRUCTURE-001 Evidence class structures-and-complexes Retrieved 2026-09-04

Source files and identifiers

The data exports include source identifiers, record hashes, and model versions. Campaign results identify completed computations and their outcomes.

Downloads:Full atlas JSON Search ledger JSON Opportunities JSON

Preprint search records

Preprints

Preprints and journal publications have separate links. Each preprint keeps its source and version.

Registered queries: 40
Completed queries: 40
Preprints in this report: 13
Records enriched from the preprint server: 6
Truncated queries: 0
Search cutoff: 2026-09-04

Downloads:Preprint collection JSON

One row per imported preprint record. Journal links identify separate publications.
Preprint	Version and date	Source	Publication links	Details
Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion10.1101/2021.09.17.460827Preprint	Version 12021-09-19	bioRxivEurope PMC PPR396484	Published article linked10.7554/eLife.73926	Sources and versions Preprint ID DOI:10.1101/2021.09.17.460827 Evidence class preprint-discovery-evidence Journal Not recorded Query IDs Q-BIORXIV-11 Metadata source europe-pmc-explicit-biorxiv Source publication field 10.7554/eLife.73926 Version 1 · 2021-09-19 · Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion details: Metadata snapshot pubs: Metadata snapshot
Mutation-induced phenotypic plasticity drives formation of a pro-metastatic tumour-intrinsic niche10.1101/2022.12.22.521159Preprint	Version 32026-08-20	bioRxivEurope PMC PPR588446	No publication link recorded	Sources and versions Preprint ID DOI:10.1101/2022.12.22.521159 Evidence class preprint-discovery-evidence Journal Not recorded Query IDs Q-BIORXIV-01, Q-BIORXIV-11, Q-BIORXIV-31 Metadata source europe-pmc-explicit-biorxiv Source publication field NA Version 1 · 2022-12-23 · RNF43 mutations facilitate mucinous colorectal cancer metastasis via formation of a tumour-intrinsic niche Version 2 · 2023-04-15 · RNF43 mutations facilitate colorectal cancer metastasis via formation of a tumour-intrinsic niche Version 3 · 2026-08-20 · Mutation-induced phenotypic plasticity drives formation of a pro-metastatic tumour-intrinsic niche details: Metadata snapshot pubs: Metadata snapshot
Single-cell multi-omics reveals insights into differentiation of rare cell types in mucinous colorectal cancer10.1101/2024.02.01.578409Preprint	Version 12024-02-05	bioRxivEurope PMC PPR801524	No publication link recorded	Sources and versions Preprint ID DOI:10.1101/2024.02.01.578409 Evidence class preprint-discovery-evidence Journal Not recorded Query IDs Q-BIORXIV-01, Q-BIORXIV-11 Metadata source europe-pmc-explicit-biorxiv Source publication field NA Version 1 · 2024-02-05 · Single-cell multi-omics reveals insights into differentiation of rare cell types in mucinous colorectal cancer details: Metadata snapshot pubs: Metadata snapshot
Glycosite Mapping and in situ Mass Spectrometry Imaging of MUC2 Glycopeptides via On-slide Digestion with Mucinase StcE10.1101/2024.09.16.613285Preprint	Version 12024-09-20	bioRxivEurope PMC PPR912172	No publication link recorded	Sources and versions Preprint ID DOI:10.1101/2024.09.16.613285 Evidence class preprint-discovery-evidence Journal Not recorded Query IDs Q-BIORXIV-01 Metadata source europe-pmc-explicit-biorxiv Source publication field NA Version 1 · 2024-09-20 · Glycosite Mapping and in situ Mass Spectrometry Imaging of MUC2 Glycopeptides via On-slide Digestion with Mucinase StcE details: Metadata snapshot pubs: Metadata snapshot
Signaling downstream of tumor-stroma interaction regulates mucinous colorectal adenocarcinoma apicobasal polarity10.1101/2024.11.20.624298Preprint	Version 12024-11-21	bioRxivEurope PMC PPR944052	Published article linked10.1038/s41467-026-75127-0	Sources and versions Preprint ID DOI:10.1101/2024.11.20.624298 Evidence class preprint-discovery-evidence Journal Not recorded Query IDs Q-BIORXIV-01, Q-BIORXIV-11 Metadata source europe-pmc-explicit-biorxiv Source publication field 10.1038/s41467-026-75127-0 Version 1 · 2024-11-21 · Signaling downstream of tumor-stroma interaction regulates mucinous colorectal adenocarcinoma apicobasal polarity details: Metadata snapshot pubs: Metadata snapshot
Age-specific trends in colorectal, appendiceal, and anal tumour incidence by histological subtype in Australia from 1990 to 2020: a population-based time-series analysis10.1101/2025.04.21.25326138Preprint	Version 12025-04-24	medRxivEurope PMC PPR1009623	Published article linked10.1016/j.lanwpc.2025.101728	Sources and versions Preprint ID DOI:10.1101/2025.04.21.25326138 Evidence class preprint-discovery-evidence Journal Not recorded Query IDs Q-BIORXIV-11 Metadata source europe-pmc-explicit-medrxiv Source publication field 10.1016/j.lanwpc.2025.101728 Version 1 · 2025-04-24 · Age-specific trends in colorectal, appendiceal, and anal tumour incidence by histological subtype in Australia from 1990 to 2020: a population-based time-series analysis details: Metadata snapshot details: Metadata snapshot pubs: Metadata snapshot
Establishment and validation of a postoperative predictive model for patients with colorectal mucinous adenocarcinoma10.21203/rs.3.rs-1861874/v1Preprint	Version 12022-07-26	Research SquareEurope PMC PPR523941	No publication link recorded	Sources and versions Preprint ID DOI:10.21203/rs.3.rs-1861874/v1 Evidence class preprint-discovery-evidence Journal Not recorded Query IDs Q-BIORXIV-01 Metadata source not-requested-non-10.1101-doi Source publication field Not recorded Version 1 · 2022-07-26 · Europe PMC PPR523941
Survival after Curative Resection for Stage I Colorectal Mucinous Adenocarcinoma10.21203/rs.3.rs-21102/v2Preprint	Version 22020-06-22	Research SquareEurope PMC PPR178802	No publication link recorded	Sources and versions Preprint ID DOI:10.21203/rs.3.rs-21102/v2 Evidence class preprint-discovery-evidence Journal Not recorded Query IDs Q-BIORXIV-01 Metadata source not-requested-non-10.1101-doi Source publication field Not recorded Version 1 · 2020-04-08 · Europe PMC PPR147303 Version 2 · 2020-06-22 · Europe PMC PPR178802
Patients with Increased Levels of Fusobacterium Tumoral Abundance are Associated with Better Outcomes in Mucinous Colorectal Cancer.10.21203/rs.3.rs-2255993/v1Preprint	Version 12022-11-23	Research SquareEurope PMC PPR575984	No publication link recorded	Sources and versions Preprint ID DOI:10.21203/rs.3.rs-2255993/v1 Evidence class preprint-discovery-evidence Journal Not recorded Query IDs Q-BIORXIV-11 Metadata source not-requested-non-10.1101-doi Source publication field Not recorded Version 1 · 2022-11-23 · Europe PMC PPR575984
Transcriptomic Landscape Of Colorectal Mucinous Adenocarcinoma Has Similarity With Intestinal Goblet Cells Differentiation10.21203/rs.3.rs-3033737/v1Preprint	Version 12023-06-12	Research SquareEurope PMC PPR674705	No publication link recorded	Sources and versions Preprint ID DOI:10.21203/rs.3.rs-3033737/v1 Evidence class preprint-discovery-evidence Journal Not recorded Query IDs Q-BIORXIV-01, Q-BIORXIV-11 Metadata source not-requested-non-10.1101-doi Source publication field Not recorded Version 1 · 2023-06-12 · Europe PMC PPR674705
Clinical Treatment Of Colorectal Mucinous Adenocarcinoma Could Be Discriminate From Adenocarcinoma: Genesis And Immune Microenvironment Differences On Transcript Level10.21203/rs.3.rs-3212530/v1Preprint	Version 12023-08-23	Research SquareEurope PMC PPR709776	No publication link recorded	Sources and versions Preprint ID DOI:10.21203/rs.3.rs-3212530/v1 Evidence class preprint-discovery-evidence Journal Not recorded Query IDs Q-BIORXIV-01, Q-BIORXIV-11 Metadata source not-requested-non-10.1101-doi Source publication field Not recorded Version 1 · 2023-08-23 · Europe PMC PPR709776
Colorectal mucinous adenocarcinoma with signet-ring cells: a case report10.21203/rs.3.rs-9746720/v1Preprint	Version 12026-05-31	Research SquareEurope PMC PPR1242577	No publication link recorded	Sources and versions Preprint ID DOI:10.21203/rs.3.rs-9746720/v1 Evidence class preprint-discovery-evidence Journal Not recorded Query IDs Q-BIORXIV-11 Metadata source not-requested-non-10.1101-doi Source publication field Not recorded Version 1 · 2026-05-31 · Europe PMC PPR1242577
Proteomics-Enhanced AI-Digital Pathology in Metastatic Mucinous Colorectal Carcinoma: A Case Report10.64898/2026.03.02.709044Preprint	Version Not recorded2026-03-04	bioRxivEurope PMC PPR1221412	No publication link recorded	Sources and versions Preprint ID DOI:10.64898/2026.03.02.709044 Evidence class preprint-discovery-evidence Journal Not recorded Query IDs Q-BIORXIV-01, Q-BIORXIV-11 Metadata source not-requested-non-10.1101-doi Source publication field Not recorded

View all registered queries

Query limits apply to each registered search. Zero results remain visible.
Query	Scope	Hits	Retrieved	Limit	Coverage and source
Q-BIORXIV-01	disease-associationcore-disease	9	9	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND (gene OR protein OR antigen OR receptor OR target OR biomarker) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND (gene OR protein OR antigen OR receptor OR target OR biomarker)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-02	disease-associationcontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("fluoropyrimidine exposure") AND (gene OR protein OR antigen OR receptor OR target OR biomarker) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("fluoropyrimidine exposure") AND (gene OR protein OR antigen OR receptor OR target OR biomarker)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-03	disease-associationcontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("left-sided colon") AND (gene OR protein OR antigen OR receptor OR target OR biomarker) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("left-sided colon") AND (gene OR protein OR antigen OR receptor OR target OR biomarker)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-04	disease-associationcontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("metastatic progression") AND (gene OR protein OR antigen OR receptor OR target OR biomarker) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("metastatic progression") AND (gene OR protein OR antigen OR receptor OR target OR biomarker)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-05	disease-associationcontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("MSS-like public cohorts") AND (gene OR protein OR antigen OR receptor OR target OR biomarker) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("MSS-like public cohorts") AND (gene OR protein OR antigen OR receptor OR target OR biomarker)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-06	disease-associationcontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("oxaliplatin exposure") AND (gene OR protein OR antigen OR receptor OR target OR biomarker) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("oxaliplatin exposure") AND (gene OR protein OR antigen OR receptor OR target OR biomarker)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-07	disease-associationcontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("proficient mismatch repair") AND (gene OR protein OR antigen OR receptor OR target OR biomarker) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("proficient mismatch repair") AND (gene OR protein OR antigen OR receptor OR target OR biomarker)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-08	disease-associationcontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("regional lymph node dissemination") AND (gene OR protein OR antigen OR receptor OR target OR biomarker) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("regional lymph node dissemination") AND (gene OR protein OR antigen OR receptor OR target OR biomarker)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-09	disease-associationcontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("stage III node-positive disease") AND (gene OR protein OR antigen OR receptor OR target OR biomarker) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("stage III node-positive disease") AND (gene OR protein OR antigen OR receptor OR target OR biomarker)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-10	disease-associationcontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("treatment-persistent malignant epithelial cells") AND (gene OR protein OR antigen OR receptor OR target OR biomarker) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("treatment-persistent malignant epithelial cells") AND (gene OR protein OR antigen OR receptor OR target OR biomarker)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-11	surface-identitycore-disease	10	10	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-12	surface-identitycontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("fluoropyrimidine exposure") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("fluoropyrimidine exposure") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-13	surface-identitycontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("left-sided colon") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("left-sided colon") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-14	surface-identitycontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("metastatic progression") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("metastatic progression") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-15	surface-identitycontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("MSS-like public cohorts") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("MSS-like public cohorts") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-16	surface-identitycontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("oxaliplatin exposure") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("oxaliplatin exposure") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-17	surface-identitycontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("proficient mismatch repair") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("proficient mismatch repair") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-18	surface-identitycontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("regional lymph node dissemination") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("regional lymph node dissemination") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-19	surface-identitycontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("stage III node-positive disease") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("stage III node-positive disease") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-20	surface-identitycontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("treatment-persistent malignant epithelial cells") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("treatment-persistent malignant epithelial cells") AND (cell surface OR plasma membrane OR extracellular OR ectodomain OR surfaceome OR transmembrane)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-21	surface-proteomicscore-disease	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-22	surface-proteomicscontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("fluoropyrimidine exposure") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("fluoropyrimidine exposure") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-23	surface-proteomicscontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("left-sided colon") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("left-sided colon") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-24	surface-proteomicscontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("metastatic progression") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("metastatic progression") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-25	surface-proteomicscontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("MSS-like public cohorts") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("MSS-like public cohorts") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-26	surface-proteomicscontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("oxaliplatin exposure") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("oxaliplatin exposure") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-27	surface-proteomicscontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("proficient mismatch repair") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("proficient mismatch repair") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-28	surface-proteomicscontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("regional lymph node dissemination") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("regional lymph node dissemination") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-29	surface-proteomicscontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("stage III node-positive disease") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("stage III node-positive disease") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-30	surface-proteomicscontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("treatment-persistent malignant epithelial cells") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("treatment-persistent malignant epithelial cells") AND (surface proteomics OR cell-surface proteome OR cell surface capture OR glycoproteomics OR membrane proteomics)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-31	interventioncore-disease	1	1	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-32	interventioncontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("fluoropyrimidine exposure") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("fluoropyrimidine exposure") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-33	interventioncontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("left-sided colon") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("left-sided colon") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-34	interventioncontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("metastatic progression") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("metastatic progression") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-35	interventioncontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("MSS-like public cohorts") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("MSS-like public cohorts") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-36	interventioncontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("oxaliplatin exposure") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("oxaliplatin exposure") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-37	interventioncontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("proficient mismatch repair") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("proficient mismatch repair") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-38	interventioncontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("regional lymph node dissemination") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("regional lymph node dissemination") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-39	interventioncontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("stage III node-positive disease") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("stage III node-positive disease") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot
Q-BIORXIV-40	interventioncontext-overlay	0	0	100	complete-within-100-record-cutoff Query and source ("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("treatment-persistent malignant epithelial cells") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand) (("colorectal mucinous adenocarcinoma" OR "mucinous colon adenocarcinoma" OR "mucinous colorectal cancer") AND ("treatment-persistent malignant epithelial cells") AND (antibody OR antibody-drug conjugate OR bispecific OR CAR-T OR ligand OR inhibitor OR agonist OR antagonist OR radioligand)) AND PUB_TYPE:Preprint AND FIRST_PDATE:[1900-01-01 TO 2026-09-04] Search snapshot